[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-435111-105":59,"doc-detail-435111-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","role-of-sodium-glucose-cotransporter-2-inhibitors-in-liver-diseases","Role of sodium-glucose cotransporter 2 inhibitors in liver diseases","","Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce renal glucose reabsorption and increase urinary excretion of glucose, sodium, and water, extending benefits beyond diabetes management into liver health. Evidence synthesized across studies highlights effects on metabolic dysfunction-associated steatotic liver disease through modulation of oxidative stress, inflammation, and autophagy, with potential reduction of steatosis and inflammatory progression. In cirrhosis, findings suggest decreased paracentesis requirement and lower mortality in diuretic-resistant ascites, alongside emerging links to hepatocellular carcinoma prevention and improved survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/role-of-sodium-glucose-cotransporter-2-inhibitors-in-liver-diseases/435111/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/role-of-sodium-glucose-cotransporter-2-inhibitors-in-liver-diseases/435111.png","ImageObject",300,407,{"name":92,"@type":93},"Aldword","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How do SGLT2 inhibitors influence liver health beyond glycemic control?","Question",{"text":112,"@type":113},"They promote urinary glucose, sodium, and water excretion and may affect liver disease through mechanisms linked to oxidative stress, inflammation, and autophagy. These processes are implicated in metabolic dysfunction-associated steatotic liver disease progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What benefits have been reported for patients with liver cirrhosis and ascites?",{"text":117,"@type":113},"SGLT2 inhibitors have been associated with reduced need for large-volume paracentesis and lower mortality, suggesting potential benefit in managing diuretic-resistant ascites.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the proposed role of SGLT2 inhibitors in hepatocellular carcinoma (HCC)?",{"text":121,"@type":113},"Emerging evidence indicates modulation of molecular pathways related to HCC, including inflammatory responses and oxidative stress. This supports potential use in prevention and may improve survival in patients with HCC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},435111,1790765317,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":4},2336478940917,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","| W | J | E | M | World Journal of\u003Cbr>Experimental Medicine |\n| --- | --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Exp Med 2025 December 20; 15(4): 106403  \nDOI: 10.5493/wjem.v15.i4.106403 ISSN 2220-315x (online)  \nMINIREVIEWS  \nRole of sodium-glucose cotransporter 2 inhibitors in liver diseases  \nPrajna Anirvan, Suprabhat Giri, Sayan Malakar, Dibya Lochan Praharaj  \nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade A, Grade B, Grade D, Grade E  \nNovelty: Grade A, Grade B, Grade D  \nCreativity or Innovation: Grade A, Grade B, Grade C  \nScientific Significance: Grade A, Grade C, Grade C  \nP-Reviewer: Gupta MK, PhD, Postdoctoral Fellow, Germany; Wu Y, MD, PhD, Professor, China; Zhang JF, Chief Pharmacist, Deputy Director, Research Fellow, China  \nReceived: February 25, 2025  \nRevised: April 28, 2025  \nAccepted: August 13, 2025  \nPublished online: December 20, 2025  \nProcessing time: 297 Days and 14.8 Hours  \nPrajna Anirvan, Department of Gastroenterology, Institute of Medical Sciences and SUM Hospital Campus II, Bhubaneswar 754001, Odisha, India  \nSuprabhat Giri, Dibya Lochan Praharaj, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Bhubaneswar 751024, Odisha, India  \nSayan Malakar, Department of Gastroenterology, King George Medical University, Lucknow 226003, Uttar Pradesh, India  \nCo-first authors: Prajna Anirvan and Suprabhat Giri.  \nCorresponding author: Suprabhat Giri, DM, MD, Associate Professor, Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5 KIIT Rd, Patia, Bhubaneswar 751024, Odisha, [India.](India. supg19167@gmail.com)[ supg19167@gmail.com](India. supg19167@gmail.com)  \nAbstract  \nSodium-glucose cotransporter 2 (SGLT2) inhibitors compete with the SGLT2 protein for glucose binding in the renal tubules, reducing glucose reabsorption in the kidneys. This in turn leads to increased excretion of glucose, sodium, and water into the urine. These inhibitors, initially developed for diabetes management, have shown potential benefits beyond glycemic control, impacting liver health through various mechanisms. They have emerged as promising agents in managing liver conditions, including fatty liver disease, cirrhosis, and the prevention of hepatocellular carcinoma (HCC) . They modulate processes like oxidative stress, inflammation, and autophagy, which are implicated in metabolic dysfunction-associated steatotic liver disease pathogenesis, potentially reducing steatosis and inflammation and preventing progression to more severe liver conditions. In patients with liver cirrhosis, SGLT2 inhibitors have been associated with a reduced need for large-volume paracentesis and lower mortality rates, indicating their potential in managing diuretic-resistant ascites. SGLT2 inhibitors have shown potential in modulating molecular pathways involved in HCC, such as inflammatory responses and oxidative stress, that could justify their use in the prevention of HCC and improving survival in patients with HCC. The present review synthesized findings from multiple studies to elucidate the role of SGLT2 inhibitors in these liver conditions.  \nKey Words: Sodium-glucose cotransporter 2 inhibitors; Dapagliflozin; Empaglifozin; Metabolic dysfunction-associated steatotic liver disease; Cirrhosis  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJEM  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 20, 2025  Volume 15  Issue 4   \nAnirvan P et al. SGLT2 inhibitors in liver diseases  \nCore Tip: Sodium-glucose cotransporter 2 inhibitors, primarily developed for diabetes, have shown potential benefits in managing liver conditions. Studies report improved liver enzymes, lip","cbCaircuVBIhxwXn","https://ap.wps.com/l/cbCaircuVBIhxwXn","pdf",1117772,16,"English","# Abstract\n# Core Tip\n# Introduction","[{\"question\":\"How do SGLT2 inhibitors influence liver health beyond glycemic control?\",\"answer\":\"They promote urinary glucose, sodium, and water excretion and may affect liver disease through mechanisms linked to oxidative stress, inflammation, and autophagy. These processes are implicated in metabolic dysfunction-associated steatotic liver disease progression.\"},{\"question\":\"What benefits have been reported for patients with liver cirrhosis and ascites?\",\"answer\":\"SGLT2 inhibitors have been associated with reduced need for large-volume paracentesis and lower mortality, suggesting potential benefit in managing diuretic-resistant ascites.\"},{\"question\":\"What is the proposed role of SGLT2 inhibitors in hepatocellular carcinoma (HCC)?\",\"answer\":\"Emerging evidence indicates modulation of molecular pathways related to HCC, including inflammatory responses and oxidative stress. This supports potential use in prevention and may improve survival in patients with HCC.\"}]","Role of sodium-glucose cotransporter 2 inhibitors in liver diseases | PDF",1790671986]